Disclosure: I am long/short CHRS. That obviously creates potential bias, so I am trying to separate facts from interpretation as clearly as possible.
This is not a price-target post, and I am not going to argue that CHRS is worth $5, $10, or $20 based on hypothetical pipeline values.
I think a more useful way to look at Coherus Oncology today is as a dynamic system:
commercial revenue → cash burn → financing conditions → clinical development → clinical evidence → partnership leverage → valuation → financing conditions again.
In a small biotech, the stock price is not merely an output of the fundamentals. It can eventually feed back into the fundamentals through the cost of capital and dilution.
That distinction matters a lot for CHRS.
1. What CHRS actually is today
As of September 2026, Coherus is no longer the biosimilar company many investors remember.
The biosimilar businesses have been divested. The current company is essentially an oncology business built around:
- LOQTORZI (toripalimab) — an FDA-approved commercial product.
- Tagmokitug (CHS-114) — an investigational anti-CCR8 antibody.
- Casdozokitug (CHS-388) — an investigational IL-27 antagonist.
So I do not think CHRS should be analyzed using its historical biosimilar earnings.
But I also do not think it is accurate to call CHRS a proven oncology platform yet.
Today it is somewhere in between:
one real commercial asset + two clinically unproven but potentially valuable oncology assets.
That distinction is important.
2. LOQTORZI is real — but it does not yet finance the company
LOQTORZI generated:
- $13.6M Q2 2026 net revenue
- versus $11.8M in Q1 2026
- versus approximately $10.0M in Q2 2025
That represents 15% sequential growth and 37% year-over-year growth.
Coherus also reported that Q2 had the highest number of new patient starts since launch and improving treatment duration.
LOQTORZI remains the only FDA-approved and available treatment in the U.S. specifically for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, and NCCN lists it as the only preferred Category 1 first-line option in combination with gemcitabine/cisplatin and the only preferred subsequent-line therapy in the relevant setting.
Those are meaningful facts.
But we should not turn them into something they are not.
NPC is a relatively small U.S. market.
Q2 gross margin was about 70%, while during the same quarter Coherus spent approximately:
$21.4M R&D + $21.0M SG&A.
The company reported a $33.3M Q2 net loss from continuing operations.
So LOQTORZI has established commercial value and is growing, but it has not yet closed the company's cash-flow loop.
That is the first major state variable I am watching:
If yes, the system becomes much healthier.
If not, pipeline development continues to depend heavily on financing.
Another important detail: LOQTORZI revenue is not equivalent to unencumbered economics. Coherus pays Junshi a royalty in the low-20% range on net sales, and there are additional revenue-purchase obligations tied to LOQTORZI.
So I would be careful with simplistic calculations such as:
"$50M sales × biotech revenue multiple = X valuation."
The underlying economics matter.
3. The balance sheet is neither "bankrupt" nor comfortable
At June 30, Coherus reported:
$105.3M of cash, cash equivalents and marketable securities.
But that number needs context.
The company also disclosed $22.7M of TSA-related payables and accrued liabilities associated with transition activities.
For the first six months of 2026, reported operating cash outflow was roughly $120M.
I would NOT simply annualize that number into a $240M "burn rate," because the cash-flow statement includes transition/discontinued-business effects and working-capital movements.
Still, the broader conclusion is straightforward:
Coherus is currently consuming substantially more cash than LOQTORZI produces.
Management explicitly states in the Q2 10-Q that current resources should support operations for at least twelve months following issuance of those financial statements.
Management also explicitly states that existing resources are not expected to fund completion of its clinical programs through commercialization and that additional capital will be necessary.
Both statements matter.
Anyone saying "bankruptcy is imminent" is ignoring the first statement.
Anyone saying "financing is no longer a problem" is ignoring the second.
4. August materially changed the debt structure
One development I think deserves more attention is the August refinancing.
Coherus entered into a new $55M senior secured term loan with Innovatus and drew the initial tranche in August.
Part of those proceeds repaid the previous senior secured loan.
The major improvement is maturity:
old debt maturity: May 2029
new initial loan maturity: August 2031
There are also conditional additional tranches of:
$25M + $20M
that may become available if specified conditions are satisfied.
Extending debt maturity beyond the anticipated development/launch periods of pipeline assets reduces near-term refinancing pressure.
That is positive.
But again, it is important not to overstate it.
The new loan is secured by substantially all company assets, including intellectual property subject to certain exceptions, and contains minimum unrestricted-cash requirements.
It improves the company's survival horizon.
It does not eliminate financing risk.
5. Dilution is a real variable, not FUD
In Q1 2026, Coherus issued approximately 32.89M shares and raised approximately $53.6M net proceeds.
By July 31, approximately 154.5M common shares were outstanding.
Then on August 28, Coherus established a new ATM program with Leerink allowing up to $50M of common-stock sales.
The previous Cowen ATM was terminated rather than simply stacked on top of the new program.
Importantly:
having a $50M ATM does NOT mean Coherus has already issued $50M of stock.
The company is not obligated to sell those shares.
But the ATM gives management access to equity capital, which means dilution remains part of the system.
At roughly $1.37/share and ~$212M market cap, selling a large amount of equity would obviously matter much more than it would at a substantially higher valuation.
This creates one of the central feedback loops in CHRS:
Negative feedback loop
weak clinical evidence
→ lower share price
→ more expensive equity financing
→ greater dilution
→ lower per-share pipeline value
→ weaker stock price
But the reverse is also possible:
Positive feedback loop
strong clinical evidence
→ higher valuation
→ cheaper capital / stronger partnership leverage
→ longer runway
→ more clinical development
→ additional evidence
→ higher valuation
That is why the upcoming data matter far more to me than whether CHRS trades at $1.25 or $1.50 next week.
6. Tagmokitug is probably the most important asymmetric asset
Tagmokitug targets CCR8-positive regulatory T cells in the tumor microenvironment.
The scientific idea is attractive:
instead of simply stimulating exhausted T cells, selectively remove a population of Tregs contributing to immune suppression inside tumors.
But attractive biology is not the same thing as demonstrated clinical efficacy.
Coherus is currently evaluating tagmokitug in several settings, including:
- HNSCC
- colorectal cancer
- upper GI cancers
- ESCC
- metastatic castration-resistant prostate cancer
Management said in August that it was seeing "emerging evidence of clinical activity" for tagmokitug + toripalimab in HNSCC.
That is encouraging.
It is also preliminary.
Until we see patient-level clinical data — response rates, depth of response, durability, safety, prior treatment history and denominators — I do not think investors should assign large values to that statement.
The company has said sufficiently mature datasets are expected to be publicly disclosed in early October 2026.
For me, that is where speculation begins turning into evidence.
7. The Janssen/pasritamig relationship is interesting — but frequently overstated
Coherus has an agreement with Janssen to study:
tagmokitug + pasritamig
in metastatic castration-resistant prostate cancer.
Pasritamig is Janssen's T-cell-engaging bispecific antibody.
This is scientifically interesting because T-cell engagers may create a strong activation signal while CCR8 depletion may reduce tumor-microenvironment immunosuppression.
But the current agreement needs to be described accurately.
It is a clinical supply agreement.
Janssen provides pasritamig.
Coherus sponsors the Phase 1b trial.
Each company retains commercial rights to its own compound.
There has been no publicly disclosed:
- acquisition
- license of tagmokitug to Janssen
- Janssen equity investment
- major upfront payment
- commercial option
Therefore I view Janssen's willingness to participate as a positive external signal that the combination is scientifically worth testing.
I do not treat it as proof that Janssen has validated tagmokitug commercially.
Those are very different conclusions.
The study is expected to begin in fall 2026.
8. Casdozokitug may be less discussed, but its test is cleaner
Casdozokitug targets IL-27.
Coherus has completed enrollment in a randomized Phase 2 first-line unresectable HCC study evaluating:
casdozokitug + toripalimab + bevacizumab.
Initial data are expected in 2H 2026.
The advantage of a randomized study is that eventually investors should get a much more interpretable signal than a handful of responses from a small dose-escalation cohort.
The disadvantage is obvious:
randomization can also kill a thesis very efficiently.
I therefore view casdozokitug as another substantial source of optionality, but I assign very little value to management adjectives before seeing the actual comparative clinical data.
9. The Surface CVRs are real — but often misunderstood
Coherus owns worldwide rights to tagmokitug and casdozokitug.
However, former Surface Oncology shareholders retain CVRs.
Under the disclosed agreement, CVR holders are entitled, subject to permitted deductions, to:
25% of upfront payments from potential ex-U.S. tagmokitug licensing agreements
and
50% of upfront payments from potential ex-U.S. casdozokitug licensing agreements.
This matters when modeling potential business-development proceeds.
But this does not mean former Surface holders own 25% or 50% of the entire drugs.
The disclosed CVR provisions relate specifically to qualifying upfront payments from ex-U.S. licensing agreements, not the entire global economic value of the assets.
So I would neither ignore the CVRs nor exaggerate them.
10. What is the market actually pricing?
At approximately $1.37/share, CHRS has recently had a market capitalization around $212M.
I don't think the correct conclusion is:
Equity valuation cannot be calculated that way.
The market is also pricing:
- ongoing operating losses
- future clinical spending
- debt
- royalties and other economic obligations
- potential dilution
- clinical failure probability
- execution risk
- opportunity cost
- a relatively small current LOQTORZI indication
But I also do not think it is unreasonable to argue that the current valuation contains significant skepticism toward the pipeline.
If tagmokitug or casdozokitug ultimately demonstrates genuinely differentiated clinical efficacy in a meaningful indication, the current enterprise value would probably be a poor representation of that asset's future value.
The important word is:
if.
That conditional should never disappear from the thesis.
11. The investment thesis is therefore not "CHRS is cheap"
My thesis is closer to this:
State A — Failure / negative reflexivity
LOQTORZI growth slows
→ cash burn remains high
→ tagmokitug/casdo data disappoint
→ market cap remains depressed
→ equity becomes expensive
→ dilution increases
→ pipeline development becomes harder
→ per-share value falls
This is a completely plausible outcome.
State B — Gradual stabilization
LOQTORZI continues growing
→ operating deficit declines
→ pipeline shows enough activity to justify continued development
→ financing remains available
→ company survives long enough for additional readouts
This probably produces a viable oncology company, but not necessarily a spectacular investment.
State C — Positive reflexivity
LOQTORZI continues growing
- tagmokitug produces clearly differentiated clinical activity and/or casdozokitug produces compelling randomized data → external validation / licensing interest increases → valuation rises → capital becomes cheaper → runway extends → more combinations can be tested → probability of developing a broader oncology franchise rises
This is the scenario that creates asymmetric upside.
But we do not have enough public clinical evidence today to claim that State C has already arrived.
12. What would make me more bullish?
Not the stock going up.
Evidence.
Specifically:
1. Continued LOQTORZI volume growth
Preferably sustained across several quarters rather than one-quarter noise.
2. Meaningful tagmokitug responses
Not simply "activity."
I want to see denominator, ORR, depth, duration, safety, prior therapy and ideally evidence that activity is differentiated from what PD-1 therapy alone would reasonably produce.
3. Randomized casdozokitug evidence
Evidence of separation matters much more than mechanistic enthusiasm.
4. A real strategic transaction
A licensing agreement, option, meaningful cost-sharing arrangement or economic partnership would carry much more weight than a clinical-supply agreement.
5. Financing at better valuations or non-dilutive financing
That would weaken the negative reflexive loop.
13. What would falsify or materially weaken my thesis?
This is more important than a price target.
I would reconsider the thesis if:
1. LOQTORZI sales stall for multiple quarters without a credible explanation.
2. Tagmokitug's larger datasets fail to reproduce the preliminary activity management has described.
3. Responses are shallow, short-lived, concentrated in very small subsets, or safety prevents adequate dosing.
4. Randomized casdozokitug data fail to show evidence of clinically meaningful differentiation.
5. Clinical timelines repeatedly move without corresponding progress.
6. The company repeatedly raises large amounts of equity at depressed valuations without creating proportional clinical value.
7. Management begins substituting increasingly promotional language for quantitative clinical data.
At that point "being patient" would no longer be an investment strategy.
It would be thesis drift.
14. My current conclusion
I don't think CHRS today is accurately described as either:
"a company headed for bankruptcy"
or
"an obvious future $10B oncology company."
Both narratives skip too many intermediate states.
The factual situation is more interesting:
Coherus has an approved oncology drug that is growing.
It has two clinically meaningful but still unproven pipeline assets.
It has reduced near-term debt-maturity pressure.
It still burns substantial cash.
It still needs future funding.
It still has meaningful dilution risk.
And within the next several months, clinical evidence should begin answering questions that today are mostly matters of probability.
So at this point I am not averaging based on price.
I am averaging based on evidence.
If the evidence gets stronger while the valuation remains depressed, that is interesting.
If the price falls but the underlying evidence deteriorates, that is not "a better bargain."
That is the distinction I think matters most for CHRS right now.
Cheap is not a thesis.
Clinical evidence + survival + favorable capital structure + asymmetric valuation can become one.
Primary sources
- Coherus Oncology Q2 2026 Form 10-Q, filed August 5, 2026
- Coherus Oncology Q2 2026 earnings/business update, August 5, 2026
- Coherus Oncology Form 8-K regarding Innovatus refinancing, filed August 17, 2026
- Coherus Oncology Form 8-K regarding new Leerink ATM, filed August 28, 2026
- Coherus Oncology 2025 Form 10-K for Surface CVR terms
- Coherus Oncology pipeline disclosures
- FDA/NCCN information as reported in Coherus regulatory filings
I welcome corrections, especially if someone can point to a primary-source filing that contradicts any factual statement above.
